Research and Markets (http://www.researchandmarkets.com/research/31c696/dealmaking_and_ind) has announced the addition of Decision Resources, Inc.'s new report "Dealmaking and Industry Outlook: Autoimmune and Inflammatory Diseases" to their offering.
Better diagnostics, the means to treat earlier stage-disease, disease-modifying therapies, and disease prevention are the holy grails of autoimmune and inflammatory disease drug development. However, basic science and redundant biological pathways are holding back this therapy area. In this report, we investigate the autoimmune and inflammatory disease industry. We analyze 200 deals in this therapy area for 2007, 2008, and the first five months of 2009. We assess what types of deals companies are executing and what business strategies they are deploying for future success. We discuss recent industry-shaping events, industry drivers, and barriers that are holding back this therapy area.
Questions Answered in This Report
Analyzing deals opens up a window to a company's business strategies.
- What do the 200 deals related to autoimmune and inflammatory diseases that took place in 2007, 2008, and the first five months of 2009 indicate about the business strategies of Big Biotech, Mid-Size Pharma, and Big Pharma?
- What technologies are hot?
- What new targets were licensed or optioned?
Three mega-mergers were announced in early 2009.
- What impact will these deals have on this therapy area?
- Why did Pfizer CEO Jeffrey Kindler think that Wyeth was the right answer for Pfizer?
- What trouble might Merck & Co. have with the Schering-Plough acquisition?
- What might prevent Roche from achieving its goals in its acquisition of Genentech?
The number of generics and branded generics is rising in some segments of this therapy area.
- Which diseases are seeing an increase in these types of agents and why?
- What do GlaxoSmithKline's recent deals with Aspen Pharmacare and Dr Reddy's Laboratories indicate about this company's current strategies?
Understanding biological pathways and discovering biomarkers is key to future success in the autoimmune and inflammatory disease markets.
- What are the hurdles in this arena?
- What recent deals took place relating to pharmacogenomics?
- What gene discoveries may help in at least one disease area?
Companies have a continued passion for biologics.
- What are the recent deals in this area?
- What are the 16 licensed MAbs?
- The 11 recombinant proteins?
- The 8 peptides?
Companies are scouring early-stage technology opportunities for breakthrough technologies and innovative product candidates.